Sona Nanotech Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Andrew Regan
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Purdy’s Wharf Tower II Halifax NS Canada B3J 3R7
- IPO Date
- Jul 27, 2006
- Website
- sonanano.com
- Similar Companies
- Business
- Sona Nanotech Inc. (CSE: SONA; OTCQB: SNANF) develops and commercializes proprietary gold nanorod (GNR) and gold nanoparticle technologies for biomedical applications, including targeted hyperthermia therapy (THT) for cancer treatment; CTAB-free gold nanorods under the Gemini brand; spherical gold nanoparticles branded Sona Gold; custom conjugation services; lateral flow test development and production; point-of-care diagnostics such as rapid COVID-19 antigen, bovine TB, concussion, and saliva tests; drug delivery systems; photothermal therapy; and cell imaging solutions. Founded in 2014 and headquartered in Halifax, Nova Scotia, Canada, with operations in Dartmouth, the company targets the nanotechnology life sciences sector, serving diagnostic testing platforms, cancer therapeutics, and research markets primarily in North America with potential for global expansion pending regulatory approvals. Recent developments include dosing the first patient in a THT feasibility clinical trial in 2025; reporting an 80% response rate in first-in-human THT studies; closing private placement financings raising approximately $1.6 million in 2024 to fund regulatory submissions and R&D; securing $40,000 in grant funding in April 2024 for intellectual property development; showcasing THT at the U.S. Nanotechnology Characterization Laboratory's 20th anniversary symposium; and enhancing manufacturing processes to improve yields and biocompatibility as confirmed by independent NCL assessments.
Dow rockets higher as Strait of Hormuz stays open, talks eyed
Iran's blockade of the Strait of Hormuz has wiped out a third of global helium supply, and the scramble for secure alternatives has begun
Dow powers higher as oil slump, easing tensions lift stocks
Hims & Hers shares jump as FDA begins review of restricted peptide compounds
Sona Nanotech appoints two oncologists to scientific advisory board
Sona Nanotech appoints two oncologists to scientific advisory board
Sona Nanotech reports immune activation in melanoma trial of heat-based therapy
Alien Metals shares jump 16% as joint ventures advance drilling at two Western Australia precious metal projects
FTSE 100 Live: Aero and defence stocks lead decline as Trump's Iran deadline looms
Sona Nanotech preclinical study shows tumor regression in colorectal cancer model
Sona Nanotech preclinical study shows tumor regression in colorectal cancer model
Why precision oncology may be poised for a reset: a conversation with Sona Nanotech
Sona Nanotech CEO on breakthrough cancer therapy results - ICYMI
Sona Nanotech poised for clinical breakthrough after melanoma study
Sona Nanotech reveals positive response rate in first-in-human THT cancer therapy study
Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
Sona Nanotech To Host Investor Webinar To Discuss Clinical Study
Sona Nanotech advances first-in-human cancer therapy trial
Sona Provides Update on First-In-Human Clinical Trial
Sona Nanotech launches first human trial for groundbreaking cancer therapy